PLEASANTON, Calif., Oct. 1, 2024
/PRNewswire/ -- At the Human Cell Atlas General Meeting held
September 29-30 in Milan, Italy, 10x Genomics, Inc. (Nasdaq:
TXG), a leader in single cell and spatial biology, shared new
details about its upcoming product roadmap and its ongoing strategy
to democratize access to single cell analysis.
During its Foundational Sponsor talk in the Sept. 29 Technology Showcase, 10x Genomics
announced an imminent plan to deliver "single cell for a single
cent." Through a series of new products and configurations expected
to launch this quarter, 10x Genomics intends to deliver mega-scale
single cell analysis at a cost as low as $0.01 per cell. 10x Genomics believes its
upcoming launches, which enable 2.5 million cells per run and 5
million cells per kit, will be the most cost effective single cell
products available for CRISPR screens, cell atlassing projects and
other high-throughput applications.
"We know price is an important consideration, both for new
researchers embarking on their first single cell experiment and
current customers looking to do more – whether that's analyzing
more cells or more samples, or running more experiments, more
routinely," said Michael
Schnall-Levin, Founding Scientist and Chief Technology
Officer at 10x Genomics. "By continuing to deliver single cell
technologies that offer superior performance and superior
economics, we believe we can expand the single cell opportunity,
drive widespread adoption and make single cell analysis the
standard for most biological research."
In addition to new solutions for mega-scale applications, 10x
Genomics' planned launches this quarter will feature cost effective
products to increase access to and adoption of single cell in
additional applications and use cases. These new offerings are
expected to enable researchers to perform single cell experiments,
even at a small scale, for approximately $560 per sample.
As part of the company's strategy to democratize access to
single cell analysis, 10x Genomics introduced several new products
earlier this year to drive down customer cost in multiple
directions: per cell, per sample, per experiment and per project.
This includes:
- Chromium GEM-X Technology: In March, 10x Genomics
launched the first two products on its new GEM-X technology
architecture, which enables increased sensitivity and capture
efficiency, improved robustness and scalability and a more than
two-fold reduction in cost per cell.
- Chromium Xo: Last month, 10x Genomics announced the
launch of Chromium Xo, the company's most affordable single cell
instrument. Chromium Xo delivers the high-quality data, superior
reproducibility and ease of use that the company's
instrument-powered workflows are known for, at a U.S. list price of
$25,000.
"For nearly a decade, researchers have known 10x as the single
cell technology leader," added Schnall-Levin. "Our upcoming
launches will reinforce Chromium's leadership in both high
performance and low cost, because researchers should never
have to compromise one for the other. We can't wait to show the
world what we've been working on."
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with
us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "see," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include, but are not limited to,
statements regarding 10x Genomics, Inc.'s ("10x Genomics") and
others' product launches, performance, configuration, costs,
capabilities, requirements, workflows, applications, adoption,
opportunities, leadership and pipeline. These statements are based
on management's current expectations, forecasts, beliefs,
assumptions and information currently available to management, and
actual outcomes and results could differ materially from these
statements due to a number of factors. Other risks and
uncertainties that could affect 10x Genomics' financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-announces-mega-scale-single-cell-analysis-for-one-cent-per-cell-at-human-cell-atlas-general-meeting-302264693.html
SOURCE 10x Genomics, Inc.